Seheult Jansen N, Anto Vincent, Alarcon Louis H, Sperry Jason L, Triulzi Darrell J, Yazer Mark H
Department of Pathology, University of Pittsburgh.
University of Pittsburgh School of Medicine.
Transfusion. 2018 Aug;58(8):1838-1845. doi: 10.1111/trf.14779. Epub 2018 Aug 30.
The serological safety of transfusing ≤4 units of low titer group O whole blood (LTOWB) in civilian trauma patients has been demonstrated. This study investigated clinical outcomes of LTOWB recipients compared to patients who received only conventional blood components during their resuscitation.
A retrospective analysis of trauma patients' medical records who received LTOWB during the first 24 hours of their admission was performed. Using a 12-parameter propensity matching strategy, LTOWB recipients were matched to other patients who received at least one red blood cell (RBC) unit during their first 24 hours of admission but not LTOWB. The primary outcomes were mortality and blood use.
A total of 135 patients who received LTOWB (median 2 units) were matched to 135 patients who received conventional components. There were no significant differences in the matching parameters between the groups. There were no significant differences in outcomes between the conventional component and LTOWB groups: median (interquartile range) in-hospital mortality, 24.4% vs. 18.5% (respectively, p = 0.24); 24-hour mortality, 12.6% vs. 8.9% (respectively, p = 0.33). The hospital and intensive care unit lengths of stay were not significantly different between groups. The median number of RBC units transfused, including the contribution from the LTOWB, was not significantly different between the groups. The time to normalization of elevated plasma lactate levels tended to be shorter among the LTOWB recipients compared to the conventional component recipients (median 8.1 [3.7-15.4] hr vs. 13.2 [4.4-26.8] hr, respectively, p = 0.05).
The LTOWB recipients had similar clinical outcomes compared to recipients of conventional component therapy.
已证实为民用创伤患者输注≤4单位低滴度O型全血(LTOWB)的血清学安全性。本研究调查了LTOWB接受者与复苏期间仅接受传统血液成分的患者相比的临床结局。
对入院后首24小时内接受LTOWB的创伤患者的病历进行回顾性分析。采用12参数倾向匹配策略,将LTOWB接受者与入院首24小时内接受至少1单位红细胞(RBC)但未接受LTOWB的其他患者进行匹配。主要结局为死亡率和血液使用情况。
共有135例接受LTOWB(中位数为2单位)的患者与135例接受传统成分的患者相匹配。两组之间的匹配参数无显著差异。传统成分组和LTOWB组在结局方面无显著差异:住院死亡率中位数(四分位间距)分别为24.4%和18.5%(p = 0.24);24小时死亡率分别为12.6%和8.9%(p = 0.33)。两组之间的住院时间和重症监护病房住院时间无显著差异。两组之间输注的RBC单位中位数,包括LTOWB的贡献,无显著差异。与传统成分接受者相比,LTOWB接受者血浆乳酸水平升高恢复正常的时间往往更短(分别为中位数8.1[3.7 - 15.4]小时和13.2[4.4 - 26.8]小时,p = 0.05)。
与传统成分治疗接受者相比,LTOWB接受者具有相似的临床结局。